P.K. Raveendran Nair
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by P.K. Raveendran Nair.
International Immunopharmacology | 2004
P.K. Raveendran Nair; Sonia Rodriguez; Arturo Alamo; Steven J. Melnick; Enrique Escalon; Pedro I. Garcia; Stanislaw F. Wnuk
Abstract An α-d-glucan (RR1) composed of (1→4) linked back bone and (1→6) linked branches with a molecular mass of >550 kDa and exhibiting unique immune stimulating properties is isolated and characterized from the medicinal plant Tinospora cordifolia. This novel polysaccharide is noncytotoxic and nonproliferating to normal lymphocytes as well as tumor cell lines at 0–1000 μg/ml. It activated different subsets of the lymphocytes such as natural killer (NK) cells (331%), T cells (102%), and B cells (39%) at 100 μg/ml concentration. The significant activation of NK cells is associated with the dose-dependent killing of tumor cells by activated normal lymphocytes in a functional assay. Immune activation by RR1 in normal lymphocytes elicited the synthesis of interleukin (IL)-1β (1080 pg/ml), IL-6 (21,833 pg/ml), IL-12 p70 (50.19 pg/ml), IL-12 p40 (918.23 pg/ml), IL-18 (27.47 pg/ml), IFN- γ (90.16 pg/ml), tumor necrosis factor (TNF)-α (2225 pg/ml) and monocyte chemoattractant protein (MCP)-1 (2307 pg/ml) at 100 μg/ml concentration, while it did not induce the production of IL-2, IL-4, IL-10, interferon (IFN)-α and TNF-β. The cytokine profile clearly demonstrates the Th1 pathway of T helper cell differentiation essential for cell mediated immunity, with a self-regulatory mechanism for the control of its overproduction. RR1 also activated the complements in the alternate pathway, demonstrated by a stepwise increase in C3a des Arg components. Incidentally, RR1 stimulation did not produce any oxidative stress or inducible nitric oxide synthase (iNOS) in the lymphocytes or any significant increase in nitric oxide production. The water solubility, high molecular mass, activation of lymphocytes especially NK cells, complement activation, Th1 pathway-associated cytokine profile, together with a low level of nitric oxide synthesis and absence of oxidative stress confer important immunoprotective potential to this novel α-d-glucan.
International Journal of Cancer | 2006
P.K. Raveendran Nair; Arturo Alamo; Curtis Bruce Cochrane; Enrique Escalon; Steven J. Melnick
Amooranin (AMR), a natural triterpenoid drug isolated and characterized from Amoora rohituka stem bark, is cytotoxic to SW620 human colon carcinoma cell line with an IC50 value of 2.9 μg/ml. This novel compound caused depolarization of mitochondrial membrane and decrease of membrane potential, indicating initial signal of apoptosis induction. The percentage of cells with decreased mitochondrial potential ranged from 7.4% at 1 μg/ml to 60.5% at 100 μg/ml AMR. Flow cytometric analysis of apoptosis using Annexin‐V‐FITC staining showed that the percentage of apoptotic cells ranged from 7.5% at 1 μg/ml to 59.2% at 100 μg/ml AMR. AMR‐induced apoptosis was accompanied by redistribution of cytochrome c from mitochondria to cytosol as well as down regulation of Bcl‐2 and Bcl‐XL proteins in a dose‐dependent manner. SW620 human colon carcinoma xenograft mice treated with AMR showed significant reduction in tumor growth rates compared to saline‐ and doxorubicin‐treated groups. The reduction in tumor growth rate was better in xenografts treated with 2 mg/kg AMR than 5 and 10 mg/kg treated mice. The analysis of global gene expression changes induced by AMR in xenograft tumors by microarray hybridization revealed that several genes involved in energy pathways, transport, apoptosis, immune response, nucleic acid metabolism, protein metabolism, cell growth and/or maintenance, signal transduction and cell communication, were affected by this natural cancer drug. These results suggest that the anticancer properties of AMR in SW620 human colon carcinoma cell line are mediated through its effects on functional genomics, targeting the apoptotic process.
Anticancer Research | 2005
Sonia Rodriguez; P.K. Raveendran Nair; Hugo B. Fonseca; Ziad Khatib; Enrique Escalon; Steven J. Melnick
International Immunopharmacology | 2006
P.K. Raveendran Nair; Steven J. Melnick; Enrique Escalon
Anticancer Research | 2008
Curtis Bruce Cochrane; P.K. Raveendran Nair; Steven J. Melnick; Anna P. Resek
Journal of Alternative and Complementary Medicine | 2007
P.K. Raveendran Nair; Richard T. Clèment; Steven J. Melnick
Archive | 2005
P.K. Raveendran Nair; Steven J. Melnick
Archive | 2006
P.K. Raveendran Nair; Steven J. Melnick
Blood | 2006
P.K. Raveendran Nair; Steven J. Melnick; Ziad Khatib; Enrique Escalon
Blood | 2006
P.K. Raveendran Nair; Enrique Escalon; Steven J. Melnick; Ziad Khatib